Digest Network Come funziona
Network
/
Società
Ha
Non verificato

Harmony Biosciences Holdings, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

26 comunicati stampa

Guarda tutti i comunicati
12/01/2026
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Industria
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
07/01/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Web e Social Network
Eventi
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
08/12/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
02/12/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
24/11/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
19/11/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
23/10/2025
Pubblico Esercizio/Vendita al dettaglio
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Medicina - Varie
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
24/09/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
26/08/2025
Scienza
Biotecnologia
Sanità
Salute
Farmaceutica
Eventi
Industria
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0